Research Analysts Offer Predictions for NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at William Blair issued their Q1 2026 earnings estimates for Intellia Therapeutics in a report released on Wednesday, March 26th. William Blair analyst M. Minter anticipates that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. William Blair also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($1.28) EPS and Q4 2026 earnings at ($1.35) EPS.

Other research analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Barclays lowered their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Price Performance

NTLA stock opened at $8.07 on Thursday. Intellia Therapeutics has a 1-year low of $8.03 and a 1-year high of $28.18. The business has a fifty day moving average price of $9.98 and a 200-day moving average price of $13.81. The stock has a market capitalization of $835.38 million, a P/E ratio of -1.48 and a beta of 1.97.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently bought and sold shares of the stock. Capstone Investment Advisors LLC lifted its stake in shares of Intellia Therapeutics by 1.4% in the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after purchasing an additional 831 shares during the period. Ensign Peak Advisors Inc increased its holdings in Intellia Therapeutics by 2.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after buying an additional 1,100 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after acquiring an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Intellia Therapeutics by 14.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after acquiring an additional 1,582 shares during the period. Finally, Arizona State Retirement System boosted its stake in shares of Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after acquiring an additional 1,615 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.